Adaptyx Biosciences Presents First-In-Human Continuous Multi-Day Free Cortisol Data from Wearable Sensor at ADA, Showing Time-Resolved Hormone Signals for Metabolic and Health Insights Adaptyx Biosciences, a Stanford University spinout focused on continuous molecular biosensing technologies, has reported a major clinical…
Ignite Proteomics Launches Prospective 10,000-Patient Oncology Registry to Assess Functional Proteomics in Cancer Therapy Selection Ignite Proteomics, LLC (“Ignite Proteomics”), a subsidiary of Aditxt, Inc. (NASDAQ: ADTX), has announced the launch of a large-scale prospective oncology registry designed to advance…
Beyond Anti-Aging: AV Laboratories Elevates Amino Acids as the Core of Science-Driven Skin Longevity At the AVL Molecular Research Center at the University of Colorado Boulder, AV Laboratories is conducting in-depth studies on skin cell biology to better understand the…
Azafaros Announces Publication of Phase 2 RAINBOW Study Results for Nizubaglustat in Molecular Genetics and Metabolism Journal Azafaros, a privately held biotechnology company focused on developing therapies for lysosomal storage disorders (LSDs) with a particular emphasis on neurological manifestations, has…
NEJM Publishes ASCERTAIN-V Trial Results of First All-Oral Decitabine-Cedazuridine Plus Venetoclax Regimen in AML Taiho Oncology, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for hematologic malignancies and solid tumors, has announced the publication of results from…
Mission Bio and German Research Consortium Identify Single-Cell Biomarker Signal That May Predict Motixafortide Benefit in AML Mission Bio, a leader in single-cell multiomics, has jointly announced new findings with Heidelberg University Hospital, Martin Luther University Halle-Wittenberg, the East German…
Moonlight Therapeutics Launches First-in-Human Phase I Trial of MOON101 for Peanut Allergy Moonlight Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for food allergies, has announced the initiation of its first-in-human Phase I clinical trial evaluating MOON101,…
Camizestrant Combination Reduced Risk of First and Second Disease Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 AstraZeneca has announced updated positive findings from its pivotal Phase III SERENA-6 clinical trial, reinforcing the potential of camizestrant in combination with…
Incyte Reports Positive Phase 3 frontMIND Results for Tafasitamab Plus Lenalidomide Added to R-CHOP in First-Line DLBCL and HGBL Incyte Corporation (Nasdaq: INCY) has announced positive results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in combination with…
Corsair Pharma Reports Successful Phase 1 Results for TRX-248 Transdermal System in Pulmonary Arterial Hypertension Corsair Pharma, Inc., a private biopharmaceutical company focused on innovative drug delivery technologies, has announced positive results from its first-in-human Phase 1 clinical trial evaluating…
Qurient Doses First Patient in Phase 2 Trial of Mocaciclib for CDK4/6 Inhibitor-Resistant HR-Positive Breast Cancer Qurient Co., Ltd. has announced a major clinical development milestone with the dosing of the first patient in a Phase 2 study evaluating mocaciclib…
Sumitomo Pharma America Reports Promising Early Clinical Results for Investigational CHK1 Inhibitor SMP-3124LP in Advanced Solid Tumors Sumitomo Pharma America, Inc. (SMPA) has unveiled encouraging clinical findings from its ongoing first-in-human Phase 1/2 study evaluating SMP-3124LP, an investigational checkpoint kinase…